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Xeroderma pigmentosumDe Sanctis–Cacchione (DSC) syndrome is one of the rarest, most severe forms of xeroderma pigmentosum (XP).
These patients with XP are of short stature, have mental disabilities, and develop progressive neurologic degen-
eration because of a severe inability to repair damaged DNA. Herein, we will present the case of a 9-year-old boy
who had DSC syndrome with microcephaly, severe psychomotor retardation, ataxia, and hearing loss. The cuta-
neous manifestations included giant squamous cell carcinoma (SCC) that covered the eye, multiple facial SCCs,
and pigment changes on sun-exposed areas. In addition, we include a review of reported rare cases and a brief
discussion of disease management.
© 2015 Women's Dermatologic Society. Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
De Sanctis-Cacchione syndrome (MIM#278800) is characterized by
cutaneous photosensitivity, microcephaly, mental retardation, short
stature, hypogonadism, spasticity, peripheral neuropathy, and sensori-
neural deafness (McKusick and Knifﬁn, 2010).
Case description
A 9-year-old boywas referred to the Otorhinolaryngology-Head and
Neck SurgeryDepartment at theUniversityHospital because of a rapidly
growing ulcerative lesion on the face over the past 6 months. He had a
neglected case of xeroderma pigmentosum (XP), was the offspring of
a consanguineous marriage, and had mental retardation and photosen-
sitivity. An informed consent was obtained from the patient’s parents
for this report.
Physical examination
A large, ulcerated tumor (10 × 12 cm) was observed on the left side
of the facewith involvement of the lower lid, cheek, nose, and upper lip.
The left eye was covered by the tumor (Fig. 1). Numerous crusted le-
sions were noted on the forehead, lower lip, and right cheek. The skin
on the face, neck, and limbs of sun-exposed areas appeared dry with
freckle-like pigmentary changes including hypopigmentation, hyper-
pigmentation, and atrophy (poikiloderma). A mucous membrane ex-
amination was normal, except for the left eye that was covered by the
tumor, so the eye could not be assessed.terest in publishing this article.
er Inc. on behalf of Women's DeThe patient’s general appearance included microcephaly and a
short stature. He had bilateral hearing loss. Because of severe psycho-
motor retardation, ataxia, and spastic movement, he was bedridden
and incontinent.Imaging
A maxillofacial computed tomography (CT) scan demonstrated a
large hypodense mass over the left maxilla, with involvement of the
soft tissue in this region (Fig. 2). A brain CT scan revealed severe cortical
atrophy, but no calciﬁcation or mass effect was detected. A chest X-ray
revealed no deﬁnitive abnormalities.Laboratory tests and skin biopsy
A histopathologic examination of the facial skin biopsies indicated
a diagnosis of squamous cell carcinoma (SCC). A complete blood
cell count, routine blood chemistry, and urinalysis were all within
normal limits.Treatment
The large tumor was resected with a 1-cmmargin. The eye had ocu-
lar surface lesions and corneal scarring, but therewas no tumor involve-
ment. The largest defect was reconstructed using a split-thickness skin
graft (Fig. 3). Chemoprevention with oral low-dose isotretinoin was
started. We recommended that the patient avoid sun exposure and
take vitamin D supplements. No tumor recurrence was detected at an
18-month follow-up.rmatologic Society. This is an open access article under the CC BY-NC-ND license
Fig. 1. A 9-year-old boy presented with a large ulcerated tumor on the left side of the face
with involvement of the nose, cheek, and eye. The skin on the face appeared dry with
freckle-like pigmentary changes.
Fig. 3. The large squamous cell carcinoma was resected with 1-cmmargin, and the defect
was repaired with a split-thickness skin graft.
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XP, or “dry pigmented skin,” is characterized by extreme skin
sensitivity to ultraviolet radiation (UVR) and abnormal skin pigmenta-
tion, with a high incidence of skin cancers on sun-exposed areas
(Kraemer and DiGiovanna, 1993). XP consists of a group of various
rare autosomal recessive–inherited conditions with a defective nucleic
excision repair (NER) pathway for DNA repair. Major disorders involv-
ing defective DNA repair such as XP, Cockayne syndrome (CS), and
trichothiodystrophy present with photosensitivity and overlapping ge-
netic and clinical features. However, the development of numerous
skin cancers at a young age is characteristic of XP (DiGiovanna and
Kraemer, 2012).
Typically, XP patients have a history of sunlight hypersensitivity,
freckling, and photophobia before the age of 2 years; develop their
ﬁrst skin cancer prior to the age of 10 years; and develop their ﬁrstmel-
anoma before age 30 years (DiGiovanna and Kraemer, 2012). The diag-
nosis is clinical. Conﬁrmatorymolecular genetic testing is conducted for
research purposes and is not routinely available (DiGiovanna and
Kraemer, 2012).
De Sanctis–Cacchione syndromehas been regarded as one of the rar-
est manifestations of XP with the most severe DNA repair impairment
(Cleaver et al., 1984; Cleaver and Thomas, 1988; Mittal et al., 2013). It
is recognized by the typical XP skin changes accompanied by progres-
sive neurologic degeneration, a short stature, and delayed gonadalmat-
uration. The presence of progressive neurologic involvement and age at
symptom onset correlate with the degree of DNA repair impairment
(Caldas and Rodrigues, 2013; Hessel et al., 1992). The median life span
of patients with neurologic deterioration is shorter than those withoutFig. 2. Maxillofacial computed tomography scan demonstrated a large hypodense mass
over the left maxilla with the involvement of soft tissue of this region.neurological degeneration (29 versus 37 years) (Bradford et al., 2011;
DiGiovanna and Kraemer, 2012).
In 1932, de Sanctis and Cacchione derived the term “xerodermic id-
iocy” for three brothers with XP who had microcephaly, mental deﬁ-
ciency, dwarﬁsm, gonadal hypoplasia, progressive neurologic
deterioration, deafness, and ataxia beginning at the age of 2 years (de
Sanctis and Cacchione, 1932). This condition, called DSC syndrome,
has been rarely reported. Kraemer et al. (1987) performed a review of
case reports on XP beginningwith 1874, the ﬁrst time XP was reported,
and ending with 1982. According to their review, microcephaly and
neurologic deterioration were observed in only 37 and 27, respectively,
out of a total of 830 patients. Short stature and delayed secondary sexual
development were seen in only 19 patients (Kraemer et al., 1987).
Table 1 provides a summary of some recent case reports involving
DSC syndrome.
Several neurologic abnormalities have been recognized in XP pa-
tients. A previous review (Kraemer et al., 1987) reported neurologic ab-
normalities in 18% of patients, and the most prevalent symptoms were
mental retardation, spasticity, ataxia, and microcephaly. Recently,
from a 39-year follow-up study involving 106 patients with XP, the Na-
tional Institutes of Health (NIH) revealed that 24% of patients with XP
present with progressive neurologic degeneration (Bradford et al.,
2011). Symptoms included loss of intellectual functioning, deterioration
of neurologic status, loss of hearing, areﬂexia, ataxia, peripheral neurop-
athy, and inability to walk and talk. For our patient, brain imaging re-
vealed brain atrophy with no intracranial calciﬁcations. The severity of
neurologic degeneration in patients with XP is correlated with the dif-
fuse cortical, brain stem, and cerebellar atrophy (Anttinen et al., 2008;
Fekete, 2014; Mittal et al., 2013), while brain calciﬁcation is more sug-
gestive of Cockayne syndrome (Fekete, 2014).
Recently, the NIH reported an increased frequency of different can-
cer types in patients with XP, as comparedwith the general population,
as follows: tongue cancer (×100,000), nonmelanoma skin cancer
(×10,000), melanoma (×2,000), anterior compartment of the eye sec-
ondary to sun exposure (×1,000), and brain and central nervous system
(×50) (DiGiovanna and Kraemer, 2012). Skin cancers were reported in
about 50% of patientswith XPwhohave neurologic abnormalities, a rate
that was similar to patients who have XPwithout neurologic abnormal-
ities (Anttinen et al., 2008; Kraemer et al., 1987). In our review, we
found a similar skin cancer rate of 42% among recent patients with XP
who had neurologic abnormalities (Table 1).
The increased risk of conjunctival SCC, skin cancer on sun-exposed
areas, and progressive neurologic degeneration is believed to be caused
by an impaired NER pathway in XP cells. NER is a pathway involved in
Table 1
The summary of published case reports of XP with neurologic abnormalities and known De Sanctis-Cacchione syndrome.
Author, year Patient’s
country
Patients (n) Age Sex Skin change, Skin cancer Neurologic abnormalities (n, %), comment
(Neisser 1883) Germany 2 siblings 2nd decade . XP,. Progressive neurologic degeneration
(de Sanctis C and Cacchione A
1932)
Italy 3 brothers . M XP,. ⁎ :MR, dwarﬁsm, gonadal hypoplasia
(Kraemer, Lee & Scotto 1987) Worldwide
review
(1874 to 1982)
152 12 y
(median)
F:74
M:73
XP, skin cancer in 77(50%) MR: 121(80%), Microcephaly: 37(24%), Delayed
growth:35(23%),
Areﬂexia:30(20%), Hearing loss:28(18%), Neurologic
deterioration:27(18%), Delayed sexual development: 19(12%).
(Gupta et al. 1988) India 1 8 y F XP, no cancer ⁎, but no evidence of ataxia.
(Hessel et al. 1992) USA 1 12 y M XP, BCC,SCC ⁎, but no evidence of ataxia, or hearing loss.
(Greenhaw et al. 1992) Mexico 3 siblings 8 y
7 y
10 y
M
F
F
XP(mild), no
cancer
⁎, but biochemical proﬁle of CS.
(Niederauer et al. 1992) Germany 1 6 y M XP, . ⁎
(Itoh et al. 1996) Japan 2 sibling . . XP, no cancer ⁎ , but biochemical proﬁle of CS.
(Mishra et al. 1997) India 1 4 y M XP, no cancer ⁎, also optic atrophy.
(Falcon Lincheta et al. 1998) Cuba 1 5 y M XP, skin cancer ⁎
(Riyaz and Riyaz 1999) India 1 9 m F XP, no cancer ⁎
(Mazhar and Hannan 2001) Pakistan 2 6.5 y
13 y
M
M
XP, no cancer ⁎ , also congenital glaucoma.
(Rosón et al. 2005) Spain 1 4 y M XP, no cancer ⁎
(Procianoy et al. 2006) Brazil 1 5 y F XP, Conjunctival SCCs ⁎ , aggravated SCCs after Photodynamic Therapy
(Anttinen et al. 2008) Finland
(23y follow)
11 4 y
(median)
XP, skin cancer in 6 (55%) Progressive neurologic degeneration
(Bradford et al. 2011) USA, NIH
(1971-2009)
25 . . XP,. Progressive neurologic degeneration
(Viana et al. 2011) Brazil 1 34 m M XP, no cancer ⁎ , also schizencephaly
(Caldas and Rodrigues 2013) Brazil 1 21 m F XP, SCC, AFX ⁎
(Mittal et al. 2013) India 1 10 y M XP, no cancer ⁎, but normal gonadal maturation.
(Fekete 2014) USA 1 55 y F XP, BCCs ⁎
⁎ The classic DSC syndrome deﬁned as XPwithmental retardation, short stature and hypogonadism. The neurologic abnormalities includedmicrocephaly, delayed growth, progressive
neurologic deterioration, hearing impairment, areﬂexia, ataxia and abnormal motor activity. Progressive neurologic degeneration: loss of intellectual functioning, deterioration of neuro-
logic status, impaired hearing, abnormal speech, areﬂexia, ataxia, peripheral neuropathy, and loss of ability to walk and talk. Biochemical proﬁle of Cockayne syndrome (CS): normal DNA-
excision repair and a failure of RNA synthesis with UV exposure. AFX, Atypical Fibroxanthoma. Schizencephaly: abnormal clefts in the cerebral hemispheres of the brain that connect the
ventricles to the subarachnoid space. .. Not available
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(DiGiovanna and Kraemer, 2012), psoralen (Cortés et al., 1991), and ben-
zopyrene (carcinogen in cigarette smoke that mimics UVR damage)
(Maher et al., 1977). Cumulative mutagenic DNA damage increases the
risk of cancer on exposed areas. Although neurons are not exposed to
UVR, reactive oxygen species damageDNA.Oxidativeprocessesor reduced
superoxide dismutasemight induce premature neuron death (DiGiovanna
and Kraemer, 2012; Nishigori et al., 1989; Reardon et al., 1997).
Diseasemanagementhas beenmainly supportive. It is highly recom-
mended that the patient’s family restrict the child’s exposure to sunlight
and provide the child with skin and eye protection such as sunblock,
long-sleeved clothing, and window tinting. Vitamin D supplementation
is necessary to prevent vitamin deﬁciency (DiGiovanna and Kraemer,
2012). Avoidance of cigarette smoke and other environmental carcino-
gens are recommended. Patients need to be monitored by dermatolo-
gists, ophthalmologists, and neurologists for early management of
issues (DiGiovanna and Kraemer, 2012; Mittal et al., 2013).
The earliest clinical neurologic ﬁndings are frequently an absence of
deep tendon reﬂexes and high-frequency hearing loss (DiGiovanna and
Kraemer, 2012). Theneurologic symptomsprobably start slowlywhenpa-
tients are about 2 years of age and become apparent with cognitive and
cerebellar signs in4-5 years (Anttinenet al., 2008). Therefore, deep tendon
reﬂex testing and audiometry are recommended to screen for the pres-
ence of neurologic involvement (DiGiovanna and Kraemer, 2012). Molec-
ular genetic ﬁndings have indicated that neurologic abnormalities are
more prevalent in patients with certain gene mutations that were previ-
ously known as the A (the most frequently group worldwide and in
Japan), D, and B complimentary groups for XP (Anttinen et al., 2008;
Kraemer et al., 1987; Lai et al. 2013). Neurologic abnormalities are rare
in the C complimentary group, which is the most common group in the
United States, Europe, and theMiddle East (Kraemer et al., 1987). Howev-
er, molecular genetic studies were not performed for our patient.Skin neoplasm management involves electrodessication, curettage,
surgical excision, Mohs micrographic surgery, and chemoprevention.
Mohs microsurgery ensures complete removal and allows maximum
skin preservation for future procedures in patients with XP. In this pa-
tient, unfortunately, Mohs microsurgery was not available, and the
large SCC lesion was surgically resected with a 1-cm margin.
In addition, oral isotretinoin reduces the formation of new skin can-
cers. Previously, a study by Kraemer et al. (1992) found that chemopre-
vention with a high oral dose of isotretinoin, 2 mg/kg/day, for 2 years
signiﬁcantly reduced (63%) the number of new skin cancers in patients
with XP. We initiated treatment with a lower-dose retinoid because of
the potential for the side effect of xerosis in our patient (0.5mg/kg/day).
Recent studies found that the successful application of topical
recombinant DNA repair enzymes (e.g., liposomal encapsulated T4
endonuclease V [Yarosh et al., 2001] and liposomal photolyase with
high-protection ultraviolet ﬁlters [Giustini et al., 2014]) lowers the
rate of development of actinic keratosis, SCC, and basal cell carcinoma
in patients with XP.
Conclusion
Patients with XPmay have neurologic abnormalities. Early diagnosis
of the disorder, appropriate UVR protection, and astute management
could help alleviate patients’ symptoms.
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